Multivariate logistic regression modeling was utilized to identify independent predictors of refusing RC.
INTRODUCTION AND OBJECTIVES: Despite the advantages of holmium laser (HoLEP) for concomitant treatment of prostate enucleation and lithiasis treatment (cystolitholapaxy) studies about the simultaneous use of these techniques in patients with BPH and concomitant bladder lithiasis are scarce. As a result of our enucleation program implemented in three centers in Madrid (Spain), a large series of BPH patients with large prostate volumes and high comorbidity burden, including patients with concomitant urolithiasis, was collected.
The objective of this study is to assess the influence of holmium laser cystolitholapaxy (HLC) concomitantly with holmium laser prostate enucleation (HoLEP) on patients with benign prostatic hyperplasia (BPH) presenting bladder calculi.
METHODS: Retrospective analysis of patients with BPH (with or without concomitant HLC) at three Spanish centers. Intraoperative variables (e.g., time and resected tissue), changes in functional parameters of the prostate, and frequency of complications (intraoperative, early postoperative, and at 12 months) in patients with and without HLC were compared.
RESULTS: The analysis included 963 patients aged 48 to 91 years, of which 54 (5.6%) underwent HLC to treat vesical lithiasis. Mean (range) prostate size (measured by transrectal ultrasound) was 79 (43-173) g and 91 (35-247) g for patients with and without concomitant HLC, respectively (p[0.080) All bladder calculi were successfully removed. No significant differences were found regarding enucleation and morcellation times, but total operation time was significantly higher in patients with HLC: mean (SD) of 78 (27) RESULTS: Seventy eight patients underwent HoLEP for glands >200cc3. Mean preoperative gland size was 255.9 cm3, and a mean of 157.2g was resected on final pathology. Mean enucleation time was 77 minutes, and mean morcellation time was 50.8 minutes. Patients stayed a mean of 1.8 days and had a catheter for a mean of 2.7 days. No patients were catheter dependent at last follow up. On subgroup analysis, comparing patients with preoperative gland size 200-299cc3 vs >300cc, there was no difference in mean operative time CONCLUSIONS: HoLEP provides a safe and efficient treatment option for patients who have massive gland BPH >200cm3. There was no difference in overall procedure time or enucleation time with increasing gland size, supporting previously published studies that HOLEP is a size independent intervention. There is an expected difference in morcellation time. This represents the largest series of INTRODUCTION AND OBJECTIVES: Thulium Laser enucleation of Prostate (ThuLEP) is currently one of the alternative to open prostatectomy in patients with BHP over 80 cc. Anyway large prostate glands enucleation is believed to be more complicated (despite the learning curve) and time-consuming procedure. The aim of our study is to report intraoperative, early and long term postoperative outcomes in BPH patients larger than 150 cc.
METHODS: Our prospective study included 385 patients aged 68.2 (55-85) years with chronic and acute urinary obstruction (IPSS>20, Qmax<12) due to BPH large than 150 cc. . Catheterization time was 1.7 days for group A and 8.5 days in group B. Hospital stay was 2.3 days in group A and 11.9 days in group B. Hemoglobin decrease was with a median value of 1.05 in group A vs 5.43 g/dL in group B. 27 group B patients (14.06%) required blood transfusion due to postoperative bleeding, this happened only in 3 patients in group A.. During the 3 months of follow-up, the procedures did not demonstrate a significant difference in Qmax, IPSS and PVR.
CONCLUSIONS: Despite similar results after three months from the procedure simple transvescical prostatectomy is characterized by longer postoperative hospitalization and catheterization time and more blood loss than ThuLEP. Even without statistical evidence Thu-LEP is a little bit longer surgical procedure but it proved to be a safer treatment option for BPH over 150 cc. METHODS: A total of 72 patients without urethral stricture underwent HoLEP for benign prostatic hyperplasia. Recruited patients were randomly divided into two groups (groups A and B). Patients in group A (36 patients, experimental group) received preoperative urethral dilatation and patients in group B (36 patients, control group) did not. Each patient was evaluated at 4 week, 12 weeks, and 24 weeks after surgery. The effectiveness of preoperative urethral dilatation was evaluated based on the International Prostate Symptom Score, peak urine flow rate (Qmax), voided volume, and postvoid residual volume. To diagnose urethral stricture, Qmax <10 mL/s as assessed using uroflowmetry and findings of visualization through retrograde urethrography and urethroscopy were used.
RESULTS: Among 72 initial participants, 33 patients in group A and 31 patients in group B completed the experiment. Preoperative characteristics were well balanced between groups. At each postoperative visit, there was no significant difference in voiding symptoms between groups. Two patients (6.06%) in group A and five patients (15.15%) in group B showed a Qmax <10 mL/s on uroflowmetry (P[0.013). On urethroscopy, no patient in group A (0%) and two patients in group B (6.45%) (P[0.021) showed urethral stricture after HoLEP.
CONCLUSIONS: Preoperative urethral dilatation during HoLEP decreased the incidence of urethral stricture. This procedure could be useful to reduce the risk of urethral stricture after transurethral prostate surgery.
